Iradimed Historical Income Statement

IRMD Stock

USD 43.85 1.85 4.40%

Historical analysis of Iradimed income statement accounts such as Selling And Marketing Expenses of 7.8 M or Total Revenue of 35.1 M can show how well Iradimed Co performed in making a profits. Evaluating Iradimed income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Iradimed's future profits or losses.

Cash Flow Balance Sheet Income Statement

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Iradimed latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Iradimed is a good buy for the upcoming year.

Net Income Gross Profit

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Iradimed Co. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population.

About Iradimed Income Statement Analysis

Iradimed Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Iradimed shareholders. The income statement also shows Iradimed investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Iradimed Income Statement Chart

Iradimed Co Income Statement is one of the three primary financial statements used for reporting Iradimed's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Iradimed revenue and expense. Iradimed Income Statement primarily focuses on the company's revenues and expenses during a particular period.

At present, Iradimed's Operating Income is projected to increase significantly based on the last few years of reporting. The current year's EBIT is expected to grow to about 21 M, whereas Selling General Administrative is forecasted to decline to about 9.3 M.

Selling General Administrative Selling And Marketing Expenses Total Revenue Gross Profit Ebitda

Total Revenue

Total revenue comprises all receipts Iradimed generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Gross Profit

Gross profit is a required income statement account that reflects total revenue of Iradimed Co minus its cost of goods sold. It is profit before Iradimed operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.

Most accounts from Iradimed's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Iradimed current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Iradimed Co. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population.

	2021	2022	2023	2024 (projected)
Gross Profit	32.0M	41.3M	50.2M	27.1M
Total Revenue	41.8M	53.3M	65.6M	35.1M

Gross Profit Total Revenue

Iradimed income statement Correlations

	Depreciation And Amortization	Selling General Administrative	Selling And Marketing Expenses	Total Revenue	Gross Profit	Other Operating Expenses	Operating Income	Ebit	Research Development	Ebitda	Cost Of Revenue	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Net Income From Continuing Ops	Non Operating Income Net Other	Tax Provision	Interest Income	Net Interest Income	Reconciled Depreciation	Extraordinary Items
Depreciation And Amortization		0.46	0.49	0.25	0.24	0.42	-0.24	-0.24	0.29	-0.16	0.3	0.47	-0.24	-0.27	-0.11	-0.57	-0.13	0.01	-0.94	-0.29	-0.35	0.35	-0.37
Selling General Administrative	0.46		0.91	0.92	0.92	0.97	0.6	0.6	0.93	0.65	0.92	0.98	0.61	0.56	0.67	0.28	0.64	0.72	-0.44	0.55	0.49	-0.5	0.5
Selling And Marketing Expenses	0.49	0.91		0.93	0.92	0.98	0.61	0.61	0.9	0.66	0.96	0.97	0.61	0.54	0.71	0.19	0.69	0.75	-0.43	0.52	0.47	-0.51	0.42
Total Revenue	0.25	0.92	0.93		1.0	0.97	0.79	0.79	0.94	0.82	0.99	0.95	0.79	0.64	0.83	0.47	0.82	0.8	-0.19	0.63	0.59	-0.62	0.58
Gross Profit	0.24	0.92	0.92	1.0		0.96	0.8	0.8	0.94	0.83	0.98	0.94	0.8	0.63	0.84	0.5	0.82	0.79	-0.17	0.62	0.58	-0.61	0.57
Other Operating Expenses	0.42	0.97	0.98	0.97	0.96		0.67	0.67	0.95	0.71	0.98	1.0	0.67	0.6	0.75	0.3	0.72	0.78	-0.38	0.59	0.54	-0.56	0.53
Operating Income	-0.24	0.6	0.61	0.79	0.8	0.67		1.0	0.69	1.0	0.74	0.63	1.0	0.82	0.98	0.83	0.98	0.83	0.32	0.82	0.8	-0.82	0.7
Ebit	-0.24	0.6	0.61	0.79	0.8	0.67	1.0		0.69	1.0	0.74	0.63	1.0	0.82	0.98	0.83	0.98	0.83	0.32	0.82	0.8	-0.82	0.7
Research Development	0.29	0.93	0.9	0.94	0.94	0.95	0.69	0.69		0.73	0.94	0.94	0.7	0.63	0.73	0.45	0.7	0.75	-0.22	0.61	0.58	-0.61	0.6
Ebitda	-0.16	0.65	0.66	0.82	0.83	0.71	1.0	1.0	0.73		0.77	0.68	1.0	0.81	0.98	0.8	0.98	0.85	0.25	0.8	0.79	-0.81	0.68
Cost Of Revenue	0.3	0.92	0.96	0.99	0.98	0.98	0.74	0.74	0.94	0.77		0.96	0.74	0.66	0.81	0.38	0.79	0.81	-0.25	0.65	0.6	-0.64	0.61
Total Operating Expenses	0.47	0.98	0.97	0.95	0.94	1.0	0.63	0.63	0.94	0.68	0.96		0.63	0.57	0.71	0.26	0.69	0.75	-0.43	0.55	0.5	-0.52	0.48
Income Before Tax	-0.24	0.61	0.61	0.79	0.8	0.67	1.0	1.0	0.7	1.0	0.74	0.63		0.85	0.98	0.83	0.98	0.85	0.32	0.84	0.83	-0.85	0.72
Total Other Income Expense Net	-0.27	0.56	0.54	0.64	0.63	0.6	0.82	0.82	0.63	0.81	0.66	0.57	0.85		0.86	0.63	0.85	0.9	0.25	1.0	0.99	-0.98	0.91
Net Income	-0.11	0.67	0.71	0.83	0.84	0.75	0.98	0.98	0.73	0.98	0.81	0.71	0.98	0.86		0.7	1.0	0.89	0.16	0.85	0.83	-0.84	0.71
Income Tax Expense	-0.57	0.28	0.19	0.47	0.5	0.3	0.83	0.83	0.45	0.8	0.38	0.26	0.83	0.63	0.7		0.7	0.54	0.68	0.63	0.64	-0.67	0.59
Net Income From Continuing Ops	-0.13	0.64	0.69	0.82	0.82	0.72	0.98	0.98	0.7	0.98	0.79	0.69	0.98	0.85	1.0	0.7		0.88	0.19	0.84	0.82	-0.83	0.7
Non Operating Income Net Other	0.01	0.72	0.75	0.8	0.79	0.78	0.83	0.83	0.75	0.85	0.81	0.75	0.85	0.9	0.89	0.54	0.88		0.01	0.88	0.86	-0.88	0.7
Tax Provision	-0.94	-0.44	-0.43	-0.19	-0.17	-0.38	0.32	0.32	-0.22	0.25	-0.25	-0.43	0.32	0.25	0.16	0.68	0.19	0.01		0.26	0.32	-0.35	0.33
Interest Income	-0.29	0.55	0.52	0.63	0.62	0.59	0.82	0.82	0.61	0.8	0.65	0.55	0.84	1.0	0.85	0.63	0.84	0.88	0.26		1.0	-0.98	0.92
Net Interest Income	-0.35	0.49	0.47	0.59	0.58	0.54	0.8	0.8	0.58	0.79	0.6	0.5	0.83	0.99	0.83	0.64	0.82	0.86	0.32	1.0		-0.99	0.92
Reconciled Depreciation	0.35	-0.5	-0.51	-0.62	-0.61	-0.56	-0.82	-0.82	-0.61	-0.81	-0.64	-0.52	-0.85	-0.98	-0.84	-0.67	-0.83	-0.88	-0.35	-0.98	-0.99		-0.9
Extraordinary Items	-0.37	0.5	0.42	0.58	0.57	0.53	0.7	0.7	0.6	0.68	0.61	0.48	0.72	0.91	0.71	0.59	0.7	0.7	0.33	0.92	0.92	-0.9

Click cells to compare fundamentals

Iradimed Account Relationship Matchups

Iradimed income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Depreciation And Amortization	1.2M	1.3M	1.4M	670.7K	(2.0)	(1.9)
Interest Expense	395.9K	139.2K	18.6K	581.9K	669.1K	702.6K
Selling General Administrative	10.5M	12.3M	9.8M	10.7M	15.1M	9.3M
Selling And Marketing Expenses	9.2M	10.2M	10.6M	12.7M	12.1M	7.8M
Total Revenue	38.5M	31.7M	41.8M	53.3M	65.6M	35.1M
Gross Profit	29.7M	23.6M	32.0M	41.3M	50.2M	27.1M
Other Operating Expenses	29.9M	32.5M	32.0M	37.7M	45.5M	26.8M
Operating Income	8.6M	(756.1K)	9.8M	15.6M	20.0M	21.0M
Ebit	8.6M	(756.1K)	9.8M	15.6M	20.0M	21.0M
Research Development	1.4M	1.9M	1.9M	2.3M	2.9M	1.8M
Ebitda	9.9M	582.7K	11.2M	16.3M	20.0M	21.0M
Cost Of Revenue	8.8M	8.1M	9.8M	12.0M	15.4M	8.0M
Total Operating Expenses	21.1M	24.3M	22.2M	25.7M	30.1M	18.8M
Income Before Tax	9.0M	(616.9K)	9.8M	16.2M	21.7M	22.8M
Total Other Income Expense Net	395.9K	139.2K	18.6K	553.1K	1.7M	1.8M
Net Income Applicable To Common Shares	9.6M	1.4M	9.3M	12.8M	14.8M	15.5M
Net Income	9.6M	1.4M	9.3M	12.8M	17.2M	18.1M
Income Tax Expense	(587.6K)	(2.0M)	510.8K	3.4M	4.5M	4.8M
Net Income From Continuing Ops	9.6M	1.4M	9.3M	12.8M	16.3M	17.1M
Non Operating Income Net Other	395.9K	139.2K	18.6K	553.1K	636.1K	667.9K
Tax Provision	(587.6K)	(2.0M)	510.8K	3.4M	4.4M	4.7M
Interest Income	388.8K	132.2K	34.8K	581.9K	1.9M	2.0M
Net Interest Income	388.8K	132.2K	34.8K	581.9K	1.9M	2.0M
Reconciled Depreciation	1.2M	1.3M	1.4M	670.7K	(133.1K)	(126.4K)

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Iradimed is a strong investment it is important to analyze Iradimed's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Iradimed's future performance. For an informed investment choice regarding Iradimed Stock, refer to the following important reports:

How To Invest In Iradimed

Details

Is Iradimed Stock a good investment?

Details

What is Iradimed's Net Worth?

Details

Largest Health Care Equipment & Supplies Companies

View

Largest Health Care Equipment & Services Companies

View

You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.

Complementary Tools for Iradimed Stock analysis

When running Iradimed's price analysis, check to measure Iradimed's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Iradimed is operating at the current time. Most of Iradimed's value examination focuses on studying past and present price action to predict the probability of Iradimed's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Iradimed's price. Additionally, you may evaluate how the addition of Iradimed to your portfolios can decrease your overall portfolio volatility.

	Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities
	Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities
	Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences
	Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators
	Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios
	Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
	Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
	Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital
	Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments

Is Iradimed's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Iradimed. If investors know Iradimed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Iradimed listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

0.231

Dividend Share

0.15

Earnings Share

1.35

Revenue Per Share

5.202

Quarterly Revenue Growth

0.174

The market value of Iradimed is measured differently than its book value, which is the value of Iradimed that is recorded on the company's balance sheet. Investors also form their own opinion of Iradimed's value that differs from its market value or its book value, called intrinsic value, which is Iradimed's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Iradimed's market value can be influenced by many factors that don't directly affect Iradimed's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Iradimed's value and its price as these two are different measures arrived at by different means. Investors typically determine if Iradimed is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Iradimed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Iradimed Historical Income Statement

About Iradimed Income Statement Analysis

Iradimed Income Statement Chart

Total Revenue

Gross Profit

Iradimed income statement Correlations

Iradimed Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Iradimed income statement Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for Iradimed Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Gross Profit	+ 1.0	Total Revenue
Total Operating Expenses	+ 1.0	Other Operating Expenses
Ebit	+ 1.0	Operating Income
Ebitda	+ 1.0	Operating Income
Income Before Tax	+ 1.0	Operating Income
Ebitda	+ 1.0	Ebit

Reconciled Depreciation	- 0.99	Net Interest Income
Reconciled Depreciation	- 0.98	Interest Income
Reconciled Depreciation	- 0.98	Total Other Income Expense Net
Tax Provision	- 0.94	Depreciation And Amortization
Extraordinary Items	- 0.9	Reconciled Depreciation
Reconciled Depreciation	- 0.88	Non Operating Income Net Other